Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 4, 1998, Pages 623-630

  Tsuruoka, Akihiko ^a   Kaku, Yumiko ^a   Kakinuma, Hiroyuki ^a   Tsukada, Itaru ^a   Yanagisawa, Manabu ^a   Nara, Kazumasa ^a   Naito, Toshihiko ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Antifungal activity; ER 30346; Thiazole containing triazole antifungal

Indexed keywords

3 [4 (4 CYANOPHENYL)THIAZOL 2 YL ] 2 (2,4 DIFLUOROPHENYL) 1 ( 1H 1,2,4 TRIAZOL 1 YL) 2 BUTANOL; ANTIFUNGAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; DRUG CONFORMATION; DRUG SYNTHESIS; FUNGUS CULTURE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

EID: 0031955865     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.623     Document Type: Article

References (22)

1. Tsuruoka A., Kaku Y., Kakinuma H., Tsukada I., Yanagisawa M., Nara K., Naito T., Chem. Pharm. Bull., 45, 1169-1176 (1997).
2. a) Georgiev V. St., Ann. N. Y. Acad. Sci., 544, 1-3 (1988);
3. b) Lyman C. A., Walsh T. J., Drugs, 44, 9-35 (1992);
4. c) Georgopapadakou N. H., Walsh T. J., Antimicrob. Agents Chemother., 40, 279-291 (1996).
5. a) Richardson K., Brammer K. W., Marriott M. S., Troke P. F., Antimicrob. Agents Chemother., 27, 832-835 (1985);
6. b) Richardson K., Cooper K., Marriott M. S., Tarbit M. H., Troke P. F., Whittle P. J., Ann. N.Y. Acad. Sci., 544, 12-31 (1988).
7. a) Heeres J., Backx L. J. J., Cutsem J. Van, J. Med. Chem., 27, 894-900 (1984);
8. b) Espinel-Ingroff A., Shadomy S., Gebhart R. J., Antimicrob. Agents Chemother., 26, 5-9 (1984).
9. a) Cokker R. J., Harris J. R. W., J. Infect., 23, 101-103, (1991);
10. b) Odds F. C., J. Antimicrob. Chemother., 31, 463-471 (1993);
11. c) Hitchcock C. A., Biochem. Soc. Trans., 21, 10-39 (1993):
12. d) Millon L., Manteaux A., Reboux G., Drobacheff C., Monod M., Barale T., Michel-Briand Y., J. Clin. Microbiol., 32, 1115-1118 (1994);
13. e) Johnson E. M., Warnock D. W., Luker J., Porter S. R., Scully C., J. Antimicrob. Chemother., 35, 103-104 (1995);
14. f) Rex J. H., Rinaldi M. G., Pfaller M. A., Antimicrob. Agents Chemother., 39, 1-8 (1995).
15. Naito T., Kaku Y., Tsuruoka A., Kakinuma H., Tsukada I., Yanagisawa M., Nara K., Abstracts of Papers, The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sep. 1995, F91.
16. a) Konosu T., Miyaoka T., Tajima Y., Oida S., Chem. Pharm. Bull., 39, 2241-2246 (1991);
17. b) Tasaka A., Tamura N., Matsushita Y., Teranishi K., Hayashi R., Okonogi K., Itoh K., ibid., 41, 1035-1042 (1993).
18. Tsuruoka A., Negi S., Yanagisawa M., Nara K., Naito T., Minami N., Synthetic Communications, accepted.
19. Suzuki M., Nagawa M., Yakugaku Zasshi, 72, 305-308 (1952).
20. a) Naito T., Hata K., Tsuruoka A., Drugs of the Future. 21, 20-24 (1996);
21. b) Hata K., Kimura J., Miki H., Toyosawa T., Nakamura T., Katsu K., Antimicrob. Agents Chemother., 40, 2237-2242 (1996);
22. c) Hata K., Kimura J., Miki H., Toyosawa T., Moriyama M., Katsu K., ibid., 40, 2243-2247 (1996).